After months of arguments around protecting a trove of 15 million individuals’ genetic data, the U.S. Bankruptcy Court for the Eastern District of Missouri (Court) approved the sale of 23andMe Holding Co.’s assets to TTAM Research Institute. Over objections from more than 30 U.S. states citing privacy law concerns, in a 38‑page memorandum opinion issued June 27, 2025, the Court found no need for affirmative customer consent to transfer genetic data and made a striking argument about DNA property rights. Days later, it denied motions to stay the sale pending appeals from the state of California and a group of amici curiae. This article breaks down the Court’s analysis of privacy issues, including its rejection of the chief privacy ombudsman’s recommendations, and offers key takeaways for privacy practitioners. See our two-part series on the sale of 23andMe’s genetic data: “Implications of the Motions for a Privacy Ombudsman and State Laws” (Apr. 16, 2025), and “Lessons for Companies Around Sensitive Data” (Apr. 23, 2025).